Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 Outubro 2023 - 6:00PM
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on
October 10, 2023, the Compensation Committee of its Board of
Directors granted inducement equity grants to nine new employees,
consisting of inducement restricted stock units, or RSUs, covering
an aggregate of 29,250 shares of its common stock. These
inducement RSUs are subject to the terms of Travere’s 2018 Equity
Incentive Plan (“2018 Plan”), but were granted outside of the 2018
Plan and were granted as inducements material to the new employees
entering into employment with Travere in accordance with Nasdaq
Listing Rule 5635(c)(4).
The RSUs vest over four years, with 25% of the
shares vesting on each anniversary of the grant date, subject to
the new employee’s continued service relationship with Travere
through the applicable vesting dates.
About Travere
Therapeutics
At Travere Therapeutics, we are in
rare for life. We are a biopharmaceutical company that
comes together every day to help patients, families and
caregivers of all backgrounds as they navigate life with a rare
disease. On this path, we know the need for treatment options is
urgent – that is why our global team works with the rare
disease community to identify, develop and
deliver life-changing therapies. In pursuit of this
mission, we continuously seek to understand the diverse
perspectives of rare patients and to courageously forge new paths
to make a difference in their lives and provide hope – today
and tomorrow. For more information, visit travere.com
Media:Nivi NehraVice President, Corporate
Communications888-969-7879mediarelations@travere.com
Investors:Naomi EichenbaumVice President, Investor
Relations888-969-7879ir@travere.com
Travere Therapeutics (NASDAQ:TVTX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Travere Therapeutics (NASDAQ:TVTX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024